Neogen Chemicals Grants 50,200 Stock Options, Vests 4,650 Under ESOP Scheme
Neogen Chemicals granted 50,200 stock options to 55 employees under its ESOP Scheme 2024. The exercise price is ₹1,183.14. The company also vested 4,650 options from a previous grant. The total options under the scheme are capped at 2,50,000.
The grant and vesting of ESOPs are routine corporate actions for employee compensation and do not typically have a substantial immediate impact on the company's operations or market valuation.
The announcement details the grant and vesting of stock options, which is a standard employee incentive. While it involves equity, it does not immediately impact the company's financial performance or stock price significantly.
Neogen Chemicals Limited announced that its Nomination and Remuneration Committee (NRC) has approved the grant of 50,200 stock options under the "Neogen Chemicals Limited Employees Stock Option Scheme 2024" (NCL ESOP Scheme 2024). These options, convertible into an equal number of equity shares of face value ₹10 each, have been granted to 55 eligible employees of the company and its subsidiaries.
The effective date for this Tranche II Grant is February 11, 2026. The exercise price for these options is set at ₹1,183.14 per option, representing a 10% discount on the market price. The vesting schedule for this grant is as follows: 25% on April 1, 2027, another 25% on April 1, 2028, and the remaining 50% on April 1, 2029. Post-vesting, options can be exercised within two years.
Additionally, the NRC approved the vesting of 4,650 employee stock options that were granted to employees in Tranche I on April 1, 2025, under the same NCL ESOP Scheme 2024. The total number of options issuable under the NCL ESOP Scheme 2024 is capped at 2,50,000, representing approximately 0.95% of the company's total paid-up share capital.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under other investor communications. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.